ItalyItaly

Never change a winning team

01.10.2011

Parma/Baranzate – Chiesi Farmaceutici Spa has said it will lengthen its long-term collaboration with NiKem Research, which is focused on developing treatments within the respiratory therapeutic area.
The two drug developers have been cooperating since 2001, and the new deal will extend their efforts until 2014.

Chiesi specialises in products for respiratory pathologies, special care medicine and cardiovascular diseases. Its revenues exceeded a1bn in 2010. Chiesi is working together with NiKem on the development of preclinical candidates. NiKem Research was founded in 2001 as a spin-off from the GSK Research Centre in Baranzate near Milan, and has a staff of about 60.
NiKem is providing the collaboration’s design, synthesis, hit validation, and lead optimisation. The firm’s CEO Giuseppe Giardina described the partnership as “rock solid”, and said that the “current extension follows 10 years of continuous success.”

ItalyItaly

07.03.2012

Toscana Biomarkers S.r.l has entered the market for biomarkers with its first diagnostic kit. In late January, the company from Siena signed a licence agreement with DIESSE Ricerche S.r.l, based in Genoa. DIESSE will produce and...

ItalyItaly

07.03.2012

Italian researchers have reprogrammed neonatal cardiomyocytes into iPSCs that can re-differentiate toward CMs more efficiently than either cardiac fibroblast-derived iPS cells or even ES cells. (Cell Death Differ.,...

ItalyItaly

09.01.2012

Rome – A cold virus isolated from chimpanzees might work as an vector for human vaccines. Adenoviruses are principally suitable as vectors for vaccines for their ability to induce strong immune responses. But as most humans have...

ItalyItaly

16.12.2011

Milan/Turku – Italian drug developer Newron SpA has had a roller-coaster ride in the last few months. First Merck Serono decided to drop its stake in the company’s Parkinson’s Disease candidate salfinamide, and returned the...

ItalyItaly

15.12.2011

Genoa/Irvine – Researchers from the universities at Genoa and Irvine (US) have patented a new compound that blocks removal of the endo­cannabinoid painkiller anandamide from the synaptic space by a selective transport system....

ItalyItaly

01.10.2011

Milan/Turku – Biotie Therapies ASA’s announcement that it had signed an agreement to acquire Newron Pharma­ceuticals S.p.A. for €45m is both good and bad news for the Italian biotechnology sector. While Italy is losing one of its...

ItalyItaly

19.08.2011

Como – Shares in Gentium SpA lost about a third of their value on Thursday after The Italian biopharmaceutical company withdrew a marketing application for its drug Defibrotide being used against complications related to stem...

ItalyItaly

01.08.2011

Milan/London – Italy’s MolMed SpA has signed a deal with UK-based pharmaceutical giant GlaxoSmithKline to develop a production process for a gene therapy against the rare ‘bubble boy disease’. Over the next two years, GSK will...

Displaying results 1 to 10 out of 181

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-italy/article/never-change-a-winning-team.html

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • MOLOGEN7.65 EUR18.42%
  • BB BIOTECH150.50 EUR5.10%
  • CO.DON2.69 EUR4.26%

FLOP

  • 4SC0.80 EUR-8.05%
  • CYTOS0.16 CHF-5.88%
  • WILEX2.15 EUR-4.44%

TOP

  • BIOFRONTERA2.85 EUR29.5%
  • ADDEX3.30 CHF6.5%
  • BB BIOTECH150.50 EUR2.6%

FLOP

  • CYTOS0.16 CHF-33.3%
  • 4SC0.80 EUR-31.6%
  • PAION2.20 EUR-27.9%

TOP

  • SANTHERA81.90 CHF2072.4%
  • CO.DON2.69 EUR174.5%
  • PAION2.20 EUR144.4%

FLOP

  • CYTOS0.16 CHF-95.9%
  • 4SC0.80 EUR-54.8%
  • THERAMETRICS0.07 CHF-50.0%

No liability assumed, Date: 20.10.2014


Current issue

All issues

Product of the week

Products